Green Cross, MacroGenics initiates Phase I study of MGAH22

Published: 2011-01-11 06:56:00

Updated: 2011-01-11 06:56:00

Green Cross said Friday that the company and US-based MacroGenics have jointly conducted a multinational Phase I clinical trial of MGAH22, an Fc-optimized monoclonal antibody developed by MacroGenics which has been shown, in pre-clinical studies, to reduce tumor growth significantly in a broad pa...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK